GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
320
c/trialwatch·posted 1 months ago by u/cold_chromatogram31

how much of what we believe about endpoint actually comes from SURPASS threads

Press Release Receipts ×1

how much of what we believe about endpoint actually comes from SURPASS threads. I am not trying to be the "source?" guy. I would just like a source.

Read a press release and the publication three months apart. The hedging in the second one was substantial.

Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight.

Started keeping the trial identifiers straight in a note file because I kept mixing up two programmes in the same sentence.

Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.

468 up / 148 down76% upvoted12 commentsid 13xtbs9 Jun 2026

12 comments

10 in this archive, depth 2

best — the order this archive was captured in

u/yannick_salinas29 points·1 months ago

The registered protocol is public. Comparing the registered primary endpoint with the reported one is a two-minute check and it is how outcome switching gets caught.

replysharereportpermalink
u/cold_chromatogram31OP34 points·1 months ago

Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.

replysharereportpermalink
u/zaid_roos18 points·1 months ago

Same. A press release is a claim about a result; the publication is the result.

replysharereportpermalink
u/heart_rate_bump26 points·1 months ago

the confidence interval is the finding, the point estimate is the headline

replysharereportpermalink
u/aurel_mwangi17 points·1 months ago

The discontinuation numbers were the most useful thing in the paper for me and they were in a supplementary table.

replysharereportpermalink
u/yusuf_ramos11 points·1 months ago·edited

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

replysharereportpermalink
u/cold_chromatogram31OP16 points·1 months ago

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

replysharereportpermalink
u/joaquin_trevino7 points·1 months ago

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

replysharereportpermalink
u/hazard_ratio_halMOD5 points·1 months ago

Press-release posts get their own flair here. Nothing wrong with them, they are just a different kind of claim.

replysharereportpermalink
u/tomas_kimani-28 points·1 months ago

Not convinced. Cross-trial comparison between two programmes with different populations and designs is not a comparison.

replysharereportpermalink
About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.com
Sponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.